JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

Home・Elenco Azioni・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

24.3 -1.14

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

24.09

Massimo

24.77

Metriche Chiave
By Trading Economics
Entrata	675K 53M
Vendite	1.8M 148M
P/E Media del settore	14.029 90.422
Margine di Profitto	35.57
Dipendenti	181
EBITDA	1.7M 80M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+38.32% upside

Dividendi
By Dow Jones
Utili prossimi	25 feb 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	325M 2.9B
Apertura precedente	25.44
Chiusura precedente	24.3

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

N/A / 24.28 Supporto e resistenza

Catalyst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

30 gen 2026, 20:14 UTC

Acquisizioni, Fusioni, Takeovers

Reddy Ice to Buy Arctic Glacier, DOJ Requires Certain Divestitures

30 gen 2026, 23:47 UTC

Acquisizioni, Fusioni, Takeovers

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- WSJ

30 gen 2026, 23:47 UTC

Acquisizioni, Fusioni, Takeovers

Nvidia, OpenAI in Talks to Revise Nature of Broader Partnership, Sources Say -- WSJ

30 gen 2026, 23:47 UTC

Acquisizioni, Fusioni, Takeovers

Nvidia CEO Jensen Huang Has Privately Told Colleagues That Deal Is Non-Binding, Sources Say -- WSJ

30 gen 2026, 23:47 UTC

Acquisizioni, Fusioni, Takeovers

Nvidia's Huang Has Privately Criticized OpenAI's Business Strategy, Sources Say -- WSJ

30 gen 2026, 23:47 UTC

Acquisizioni, Fusioni, Takeovers

OpenAI, Nvidia Deal Talks Stalled in Recent Months, Sources Say -- WSJ

30 gen 2026, 23:47 UTC

Acquisizioni, Fusioni, Takeovers

Nvidia's Huang Expressed Concerns Over Competition OpenAI Faces From Anthropic, Google, Sources Say -- WSJ

30 gen 2026, 23:47 UTC

Acquisizioni, Fusioni, Takeovers

Nvidia Weighing Equity Investment of Tens of Billions of Dollars Into OpenAI, Sources Say -- WSJ

30 gen 2026, 23:47 UTC

Acquisizioni, Fusioni, Takeovers

Negotiations Over $100B OpenAI, Nvidia Deal Stall, Sources Say -- WSJ

30 gen 2026, 23:41 UTC

Discorsi di Mercato

Deckers Outdoor Seen as Undervalued -- Market Talk

30 gen 2026, 23:12 UTC

Acquisizioni, Fusioni, Takeovers

Supreme Court of British Columbia Approves Fortescue Purchase of Alta Copper

30 gen 2026, 22:20 UTC

Utili

Verizon Posts Strong Subscriber Gains Under New CEO -- WSJ

30 gen 2026, 22:10 UTC

Discorsi di Mercato

Disney CEO's Exit Plan Marks Abrupt End to Messy Succession -- Market Talk

30 gen 2026, 21:50 UTC

Discorsi di Mercato

Utili

Tech, Media & Telecom Roundup: Market Talk

30 gen 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

30 gen 2026, 21:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

30 gen 2026, 21:42 UTC

Utili

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30 gen 2026, 21:36 UTC

Utili

GE Aerospace and GE Vernova Issue Their Annual Reports. They Contain Messages for Investors. -- Barrons.com

30 gen 2026, 21:33 UTC

Utili

Tesla Stock Rebounds From Earnings Dip. SpaceX Is Helping. -- Barrons.com

30 gen 2026, 20:42 UTC

Utili

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30 gen 2026, 20:37 UTC

Acquisizioni, Fusioni, Takeovers

Why a Ruling Over CK Hutchison's Panama Canal Ports Matters -- and What's Next -- WSJ

30 gen 2026, 20:20 UTC

Discorsi di Mercato

Oil Posts Weekly Gains on U.S.-Iran Tensions -- Market Talk

30 gen 2026, 20:13 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Rise on Weather-Driven Demand -- Market Talk

30 gen 2026, 19:52 UTC

Utili

Visa and Amex Results Point to a Strong Holiday Season for Retailers -- Barrons.com

30 gen 2026, 19:29 UTC

Discorsi di Mercato

Utili

KLA Guidance Only 'Tepid' as Memory Rally Favors Peers -- Market Talk

30 gen 2026, 19:09 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

30 gen 2026, 19:09 UTC

Discorsi di Mercato

Next Canadian Inflation Release Pushed Back a Day to Not Clash With Holiday -- Market Talk

30 gen 2026, 19:07 UTC

Discorsi di Mercato

Canada Performing Well Below Economic Potential -- Market Talk

30 gen 2026, 18:46 UTC

Utili

'All Boats Are Rising' in Data and Memory, Says Western Digital's CFO. Just Look at the Stocks. -- Barrons.com

30 gen 2026, 18:34 UTC

Utili

Exxon, Chevron Post Slimmest Annual Profits Since 2021 -- 2nd Update

Confronto tra pari

Modifica del prezzo

Catalyst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

38.32% in crescita

Previsioni per 12 mesi

Media 34 USD 38.32%

Alto 35 USD

Basso 33 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

N/A / 24.28Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.